Human immunodeficiency virus and human T-cell leukemia virus type I in patients undergoing maintenance hemodialysis in Miami

Am J Kidney Dis. 1989 Jul;14(1):39-43. doi: 10.1016/s0272-6386(89)80091-5.

Abstract

The high prevalence of human immunodeficiency virus (HIV-1) infection in populations at risk in Miami prompted a seroepidemiologic study of both HIV-1 and the human T-cell leukemia virus type I (HTLV-I), a closely related virus, in our patients receiving chronic hemodialysis. One hundred twenty-nine patients undergoing hemodialysis in 1986 and 1987 were tested for antibody against both viral antigens by EIA (Abbott Laboratories, Abbott Park, IL). Seroreactive samples for HIV-1 and/or HTLV-I were confirmed by Western blot and, for HTLV-I, by viral cultures. Thirty patients (23.2%) were positive for retroviral infection (22 for HIV-1 alone, four for HTLV-I alone, and four for both HIV-1 and HTLV-I). The most important risk factor was intravenous drug use, followed by blood transfusion. Patients with HIV-1 had lower T4-T8 ratios and higher mortality than those with HTLV-I infection alone. It was concluded that HTLV-I, as well as HIV-1, infection is endemic in chronic dialysis centers in Miami. The clinical consequences of HTLV-I infection in relatively immunocompromised patients with chronic uremia who are undergoing chronic hemodialysis remains to be established.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Acquired Immunodeficiency Syndrome / epidemiology*
  • Cross-Sectional Studies
  • Female
  • Florida
  • HIV Antibodies / analysis
  • HIV Seropositivity / epidemiology
  • HIV-1*
  • HTLV-I Antibodies / analysis
  • HTLV-I Infections / complications
  • HTLV-I Infections / epidemiology*
  • Human T-lymphotropic virus 1 / isolation & purification
  • Humans
  • Injections, Intravenous
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / therapy
  • Male
  • Renal Dialysis*
  • Risk Factors
  • Substance-Related Disorders / complications
  • Transfusion Reaction
  • Travel

Substances

  • HIV Antibodies
  • HTLV-I Antibodies